Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Anderhub

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Letters|February 21, 2012
Centrosome amplification in tumorigenesisSimon J Anderhub, Alwin Krämer, Bettina Maier
Oncotarget|May 8, 2018
Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosisMark D Gurden, Simon J Anderhub, Amir Faisal, et al.
Molecular Cancer Therapeutics|October 3, 2019
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast CancersSimon J Anderhub, Grace Wing-Yan Mak, Mark D Gurden, et al.
British Journal of Cancer|March 24, 2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyAmir Faisal, Grace W Y Mak, Mark D Gurden, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Letters|February 21, 2012
Centrosome amplification in tumorigenesisSimon J Anderhub, Alwin Krämer, Bettina Maier
Oncotarget|May 8, 2018
Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosisMark D Gurden, Simon J Anderhub, Amir Faisal, et al.
Molecular Cancer Therapeutics|October 3, 2019
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast CancersSimon J Anderhub, Grace Wing-Yan Mak, Mark D Gurden, et al.
British Journal of Cancer|March 24, 2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyAmir Faisal, Grace W Y Mak, Mark D Gurden, et al.
Pageof 1